Abstract
Systematic reviews and meta-analyses are useful in integrating large amounts of data to inform medical practice, and it is likely that the already large number of published meta-analyses will increase further as the provisions in the Food and Drug Administration Amendments Act and other forces result in dramatically increased transparency about the design and results of clinical trials. It is critical for readers of these analyses to be capable of assessing the quality of this research.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
